Director Colin Walsh Buys $8.5M of Attovia Stock at $17, Sells $2.25M
ATTO sits 19% above its 52-week low of $16.15 on light trading volume (0.4× avg).
Summary
Director Colin Walsh bought $8.5 million of Attovia stock at $17 per share, while also selling $2.25 million in market-making transactions. The purchase adds to insider accumulation following the IPO.
Key Events · Ownership and Investor Activity · ATTO
-
Director Buys $8.5M at IPO Price
Colin Walsh purchased 500,000 shares at $17.00 on August 6, 2026, totaling $8.5 million, through Goldman Sachs entities.
-
Insider Accumulation Continues
This purchase follows Frazier Life Sciences' $10 million purchase at $17.00 reported on August 6, 2026, indicating strong insider confidence.
-
Market-Making Sales Not Personal
Walsh sold 105,807 shares for $2.25 million on August 5, but footnotes indicate these were Goldman Sachs market-making transactions, not personal divestment.
-
Preferred Stock Conversion
Series B and C Preferred Stock converted into 2,435,632 common shares on August 6, correcting a prior Form 3 administrative error.
Analysis · ATTO · Life Sciences
Director Colin Walsh, through Goldman Sachs entities, purchased 500,000 shares at $17.00 on August 6, 2026, for $8.5 million, adding to the $10 million purchase by Frazier Life Sciences reported earlier. Walsh also sold 105,807 shares on August 5 for $2.25 million at prices between $20.84 and $22.19. The net effect is a significant accumulation by insiders, with Walsh's purchase representing a strong vote of confidence at the IPO price. The sale appears to be a market-making activity by Goldman Sachs, not a personal divestment, as noted in the footnotes.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATTO was trading at $19.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $874.2M. The 52-week trading range was $16.15 to $22.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.